Phaseline

Companies › Ratio Therapeutics

Ratio Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[Ac225]RTX-2358
Actinium-225 alpha emitter conjugated to FAP-targeting antibody
FAPPhase 1Advanced Soft Tissue SarcomaJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07156565[Ac225]RTX-2358Phase 1Advanced Soft Tissue SarcomaOncologyJan 2028

Targets

FAP (1)

Companies with the same targets

Chengdu New Radiomedicine Technology Avacta Life Sciences Blue Earth Diagnostics Novartis Beijing Biotech SOFIE Philogen BioInvent International Lantheus Medical Imaging Perspective Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.